Synergen interleukin-1 receptor antagonist
Executive Summary
IND filed for IL-1ra for treatment of rheumatoid arthritis during the week of July 23. The biotech firm expects to begin Phase I clinicals shortly. Roche is Synergen's marketing partner for IL-1ra.